Pages

Monday, July 19, 2021

萊鎂醫: 居家COVID-19核酸檢驗 RT-LAMP: 1800元/劑


萊析樂™居家核酸快篩71日開賣 萊鎂醫營收成長性看俏  張秉鳳 2021.07.01萊鎂醫(6633)獲食藥署核准專案進口的居家快篩試劑-萊析樂™家用COVID-19核酸檢測組,71日起將小量在多家連鎖藥房及零售通路上架銷售,預計7月上中旬可望大量鋪貨到各家大型連鎖通路量販店;萊析樂™建議未稅售價每劑新台幣1800,部分通路同步採行預購方案,讓有意購買的民眾省下寶貴的詢問時間。萊鎂醫表示,萊析樂™採用分子增幅(RT-LAMP)技術,等於是一個微型COVID-19核酸檢測實驗室,能在11~30分鐘內得到PCR等級的檢測結果,較抗原快篩試劑更精準,也能糾出潛在感染者;為了讓有意的民眾得以進行居家COVID-19核酸檢驗,落實中央廣篩策略,在家用快篩指引出爐後公司就加速推進與通路方的合作,萊析樂™第一波優先鋪貨特定地區,包括全聯福利中心與大樹、丁丁等連鎖醫藥通路。萊鎂醫指出,此次先於國內同業引進核酸快篩,除了供居家快速採檢,對於不容停止運作的企業、工廠、金融、政府機關能起到快速精確的效果,在開始鋪貨藥局及通路之前,已經有10多家中大型企業採用萊析樂™核酸檢測產品,再加上新冠體外診斷器材(IVD)客製化開發製造業務,帶動1105月合併營收新台幣387萬元,年增503.11%,預期6月營收將受萊析樂™銷售貢獻,進一步推升公司後續幾季營業表現。萊鎂醫日前已與萊析樂™美國原廠Lucira Health, Inc.正式簽下產品台灣區經銷權,力求提供更穩定、完善的貨源與服務,為台灣地區防疫盡一份心。萊鎂醫特別提醒消費者,自行購買使用家用快篩的民眾,務必遵循衛福部家用快篩試劑指引之防疫規範內容。

博錸: 開發 新冠 檢測單次 判斷>10 個病毒 突變點


博錸開發病毒變異株試劑 獲日本官方認證 鉅亨網記者沈筱禎 台北2021/06/18醫材廠博錸 (6572-TE) 表示,與日本電化株式会社 (Denka) 共同研發的新冠變異株檢測試劑,已取得日本官方核准、上市,目前除已開始與當地大型檢測機構接洽外,也與台灣機場、各航空公司接觸。博錸指出,新冠變異株檢測試劑是透過旗下多元檢測平台 IntelliPlex,以及πCode MicroDisc 晶元磁片技術開發出來,單次可判斷超過 10 個病毒變異株突變位點,包括英國變種的 Alpha(B.1.1.7)、南非 Beta(B.1.351)Gamma(P1)、印度 Delta(B.1.617.2)、產業還在觀察的變異株 Epsilon(B1.427/B.1.429) 等。博錸表示,目前已上市的新冠疫苗,對部分新冠病毒變異株防護力仍不足,並有施打疫苗空窗期,加上快篩與 qPCR 核酸檢測無法立即判斷新冠變異病毒,需二次採檢才能確認,因此時間拉長下,除耗時,也可能讓確診者在等待報告時,錯失最佳治療時機。由於病毒變異株多為境外移入,博錸開發的新冠變異株檢測試劑,除了將在日本啟動銷售外,目前也積極在台灣推廣此產品,其中以機場出入境篩檢站為主,另外也會與各大航空公司、國際物流公司及台灣大型醫檢單位接洽。 博錸指出,未來若出現更多變異株,該產品可擴充探針檢測標的物數量,隨時因應檢測需求,且從檢測到取得報告時間約3小時,有望藉此診斷效率、降低成本。

大江 承諾$3.5 million (現金&股票) 換取 NewAge猶他廠; NewAge 擬併日本Aliven, Inc.


大江結盟NewAge 收購其猶他廠 作為大江美國總部 2021/07/12〔記者陳永吉/台北報導〕大江生醫(8436)今天宣布與納斯達克上市公司NewAge Inc.(股票代碼:NBEV)簽署意向書,擬收購NewAge位於猶他州的生產設施及代工銷售業務,並與NewAge展開長期合作之策略結盟。大江表示,NewAge總部位於美國科羅拉多州,為全渠道保健品及快銷品龍頭企業,行銷全球75國,掌握全球400,000 多個獨家經銷商和銷售網絡。大江生醫將取得NewAge位於美國佔地五萬平方公尺的工廠運營權,並接手該工廠既有代工業務,同時作為NewAge策略聯盟之製造夥伴。最快預計於今年第四季可由大江生醫正式啟用。近年來大江在美國營收占比逐漸攀高,此舉將縮短市場供應鏈,為更多美國品牌客戶即時反應服務,預計大江在美國營收將步入高速成長期。此交易為繼和康生技(1783)後,大江生醫集團化布局的最新進展,未來將持續加速國際擴張,為全球品牌客戶提供專業研發製造服務。大江生醫將以此為集團美國總部,於2023年前打造新台幣超過30億的生產規模,除建置高速自動化產線外,更將結合集團關係企業之高端檢測設備、醫材、專利原料、生活日用品等,作為布局世界級生物設計整合商社之產銷基地。大江生醫攜手NewAge,建立長期合作夥伴關係,雙方擬以現金及未來五年內業務合作為此次交易基礎。NewAge將透過大江生醫尖端科研及專業製造技術,降低其銷售商品之成本,並專注於其核心競爭力,充分利用其全球400,000多個獨家經銷商以及強勁的社交網絡,打造全球熱銷之保健品產品組合。大江生醫亦將受益於美國生產基地長期的額外營收貢獻。

Newage Inks Manufacturing Deal With Taiwan's TCI  Mon, July 12, 2021  Beverage company Newage Inc (NASDAQ: NBEV) has formed a manufacturing partnership with Taiwan-based TCI Co Ltd. In addition, Newage will sell its U.S. manufacturing operations and its office based in American Fork, Utah, to TCI. TCI will be providing a combination of $3.5 million in cash and a share of revenues over the next five years as consideration and will take over production over the next 90 days. NewAge will continue to produce its Tahitian Noni Juice extractions in its processing facility in Tahiti. NewAge expects to reduce the costs of goods sold by leveraging TCI's manufacturing expertise. NewAge also expects to benefit from significantly reduced headcount and SG&A expense that will directly impact its bottom line in 2021."TCI brings incredible technology and manufacturing expertise to the venture enabling NewAge to focus on leveraging its sales and marketing capabilities and global distribution network," said SVP of Operations, Phil Lewis. Price action: NBEV shares are trading lower by 1.86% at $2.11 in premarket on the last check Monday.

NewAge Announces Letter of Intent to Acquire Japan-Based Aliven, Inc. March 04, 2021 07:00 ET | Source: NewAge, Inc. DENVER, March 04, 2021 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), the Colorado-based healthy products company intending to become the world's leading social selling and distribution company today announced that it has entered into an agreement to acquire Aliven Inc., a highly successful Japan-based direct selling company. Tokyo-based, Aliven is one of Japan's highly recognized and admired companies in the $16B e-commerce and direct selling industry. Aliven is anticipated to bring approximately $20 million in annualized net revenue and more than $3 million in annual EBITDA to the NewAge Group in Japan that comprises the Morinda organization, ARIIX, and the fast-growing entity ZENNOA. In addition to significant top and bottom-line contribution, Aliven has more than 100,000 customers and independent representatives to add to the group of talented and dedicated leaders at NewAge. Aliven was founded 15 years ago and is led by Yasuyuki Oi. Oi-san is a highly respected leader in the industry and brings outstanding relationships with the Japanese Government and industry officials given his reputation. Oi-san commented, "We are so excited to be joining the NewAge team, and are confident that our group will add a lot of value to the combined organization. We see NewAge as the new global leader and disrupter in social and direct sales, and all of our reps will benefit from the expanding portfolio and global reach." Established 15 years ago, Aliven Inc. is one of the Japan's most well-respected companies in the industry and sells a portfolio of differentiated healthy products including Skin Care infused with cultured stem cells, Nutritional Products, and their patented Far-Infrared technology products that are were demonstrated in human trails to stimulate nitric oxide production for increased blood flow and muscle recovery and reduction of localized pain. NewAge and Aliven have been evaluating a partnership over the past months that culminated in the signing of a letter of intent and an expected signing of a definitive agreement in the coming weeks. Consideration for the acquisition of Aliven is approximately 1 million shares of NewAge common stock. Completion of the proposed transaction is subject to negotiation and execution of a definitive agreement and the satisfaction of customary conditions to closing."We see this latest opportunity to expand our Japan market, but at an even faster pace," commented Joseph Wadsworth, NewAge President for Japan and North Asia. "We had good growth in Q4 2020 in Japan, NewAge's largest market. Now, with the addition of Aliven we believe we can accelerate our pace. We expect to fully integrate Aliven into NewAge, and envision imminent cross pollination of our products, including our NONI+CBD Shots where we have first mover advantage in Japan. Our vision for this union is large-scale and not only creates more opportunities for all our representatives, but furthers our expectation to become the leading social selling and distribution company in Japan."

About NewAge, Inc. NewAge is a purpose-driven firm intending to become the world's leading social selling and distribution company. Colorado-based NewAge commercializes a portfolio of organic and healthy products worldwide through primarily a direct route-to-market system. The company competes in three major category platforms including health and wellness, healthy appearance, and nutritional performance and leads a network of more than 400,000 exclusive independent distributors and brand partners around the world. The Company operates the websites NewAge.com, Noninewage.com, Ariix.com, Mavie.com, Thelimucompany.com, Zennoa.com and a number of other individual brand websites and a number of other individual brand websites.

NewAge, Inc.(股票代碼:NBEV)前身為New Age Beverages Corporation,原先公司業務主要經營健康功能的飲料,產品項目包含即飲茶、紅茶菌、能量飲料、瓶裝水等。20207月公司完成與ARIIX等其他四家電子商務與直銷公司合併案,跨足電子商務與直銷業務。